SCHEMBL26388012

SCHEMBL26388012

Cc1cc(C(=O)NCCOCCC(=O)C(C)C)n[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC10 Q969S8 1/20 0.52
HDAC11 Q96DB2 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
HDAC9 Q9UKV0 1/20 0.52
HDAC5 Q9UQL6 1/20 0.52
ALPL P05186 2/20 0.46
CYP3A4 P08684 1/20 0.42
ALPI P09923 1/20 0.42
ALPG P10696 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
DAO P14920 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18680084 0.99 HDAC3 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL23605519 0.76 HDAC3 (0.62) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL21467387 0.74 HDAC3 (0.67) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL19607088 0.73 HDAC3 (0.74) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL11912071 0.71 SMN1; SMN2 (0.69) HDAC3HDAC1SMN1; SMN2LMNAALDH1A1
SCHEMBL22984745 0.71 HDAC3 (0.62) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18896203 0.71 DAO (0.56) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18896222 0.71 HDAC3 (0.61) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18896205 0.70 HDAC3 (0.77) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL17921779 0.69 MEN1 (0.47) SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018174-A1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION VENTANA MED SYST INC (US) 2024-01-18 US disclosed
US-11860167-B2 Application of click chemistry for signal amplification in IHC and ISH assays VENTANA MEDICAL SYSTEMS, INC. (US) 2024-01-02 US disclosed
US-11780863-B2 Quinone methide analog signal amplification VENTANA MEDICAL SYSTEMS, INC. (US) 2023-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780863-B2 Quinone methide analog signal amplification NQO2, SQOR, MRM1 HDAC3 4591/4885HDAC4 4607/4885HDAC1 3742/4885
US-11860167-B2 Application of click chemistry for signal amplification in IHC and ISH assays MKI67, TIE1, ALK HDAC3 1633/4885HDAC4 2124/4885HDAC1 2060/4885
US-20240018174-A1 QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION NQO2, SQOR, MRM1 HDAC3 4591/4885HDAC4 4607/4885HDAC1 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.